Journal of Clinical Oncology, Vol 15, 3030-3037, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group

E Work, OS Nielsen, SM Bentzen, K Fode and T Palshof
Department of Oncology, Danish Cancer Society, Aarhus, Denmark.

PURPOSE: To evaluate if the timing of chest irradiation with respect to chemotherapy would influence survival and local and distant control in patients with limited-stage small-cell lung cancer (LSCLC). PATIENTS AND METHODS: From 1981 to 1989, 199 consecutive patients with LSCLC were randomly allocated to receive initial chest irradiation (ICI; n = 99) or late chest irradiation (LCI; n = 100) given 18 weeks delayed. Both groups received the same nine cycles of combination chemotherapy: three cycles of cisplatin and etoposide and six cycles of cyclophosphamide, doxorubicin, and vincristine. In the first part of the study, prophylactic cranial irradiation (PCI) was only given to patients randomized to ICI, but after inclusion of 42 patients in the LCI arm, the protocol was changed, so that all patients received PCI independent of the timing of the chest irradiation (CI). A total of 157 patients received PCI with a radiation dose of 25 Gy in 11 fractions. RESULTS: The timing of radiotherapy had no significant effect on the 2- year overall survival rate (20% after ICI v 19% after LCI, P = .4) or the 2-year in-field recurrence rate (72% after ICI v 68% after LCI, P = .2). Median survival durations were 10.5 (ICI) and 12.0 (LCI) months. Similarly, no difference in the 2-year incidence of CNS recurrences was found between the 2 arms in patients who received PCI (19% after ICI v 13% after LCI, P = .24). Bone marrow toxicity was acceptable, as 15% developed World Health Organization (WHO) grade 4 leukocytopenia and 4% grade 4 thrombocytopenia. Grade 4 leukocytopenia was more pronounced in the ICI group. There was no difference in the frequency and severity of other toxicities between the 2 groups. CONCLUSION: Timing of CI did not significantly influence the incidence of in-field recurrences, CNS recurrences, or overall survival.

This article has been cited by other articles:

				D. J. Samson, J. Seidenfeld, G. R. Simon, A. T. Turrisi III, C. Bonnell, K. M. Ziegler, and N. Aronson Evidence for Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 314S - 323S. [Abstract] [Full Text] [PDF]

				S. G. Spiro, L. E. James, R. M. Rudd, C. W. Trask, J. S. Tobias, M. Snee, D. Gilligan, P. A. Murray, M. C. R. de Elvira, K. M. O'Donnell, et al. Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis J. Clin. Oncol., August 20, 2006; 24(24): 3823 - 3830. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, J. Vansteenkiste, A. Kester, I. Rutten, and P. Lambin Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer Ann. Onc., April 1, 2006; 17(4): 543 - 552. [Abstract] [Full Text] [PDF]

				D. De Ruysscher, M. Pijls-Johannesma, S. M. Bentzen, A. Minken, R. Wanders, L. Lutgens, M. Hochstenbag, L. Boersma, B. Wouters, G. Lammering, et al. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer J. Clin. Oncol., March 1, 2006; 24(7): 1057 - 1063. [Abstract] [Full Text] [PDF]

				S. G. Spiro and G. A. Silvestri One Hundred Years of Lung Cancer Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 523 - 529. [Abstract] [Full Text] [PDF]

				S. M. Bentzen, B. M. Atasoy, F. M. Daley, S. Dische, P. I. Richman, M. I. Saunders, K. R. Trott, and G. D. Wilson Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial J. Clin. Oncol., August 20, 2005; 23(24): 5560 - 5567. [Abstract] [Full Text] [PDF]

				D. B. Fried, D. E. Morris, C. Poole, J. G. Rosenman, J. S. Halle, F. C. Detterbeck, T. A. Hensing, and M. A. Socinski Systematic Review Evaluating the Timing of Thoracic Radiation Therapy in Combined Modality Therapy for Limited-Stage Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2004; 22(23): 4837 - 4845. [Abstract] [Full Text] [PDF]

				M. Huncharek and R. McGarry A Meta-Analysis of the Timing of Chest Irradiation in the Combined Modality Treatment of Limited-Stage Small Cell Lung Cancer Oncologist, November 1, 2004; 9(6): 665 - 672. [Abstract] [Full Text] [PDF]

				S.-H. Lee, Y. C. Ahn, H. J. Kim, D. H. Lim, S. I. Lee, E. Nam, S. H. Park, J. Park, K.-E. Lee, J. O. Park, et al. Early Concurrent Chemoradiotherapy with Prolonged Oral Etoposide and Cisplatin for Limited-stage Small-cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2003; 33(12): 620 - 625. [Abstract] [Full Text] [PDF]

				M. Reck, J. von Pawel, H.-N. Macha, E. Kaukel, K.-M. Deppermann, R. Bonnet, K. Ulm, S. Hessler, and U. Gatzemeier Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer J Natl Cancer Inst, August 6, 2003; 95(15): 1118 - 1127. [Abstract] [Full Text] [PDF]

				R Booton, M Jones, and N Thatcher Lung cancer * 7: Management of lung cancer in elderly patients Thorax, August 1, 2003; 58(8): 711 - 720. [Full Text] [PDF]

				J. Huang, L. Barbera, M. Brouwers, G. Browman, and W. J. Mackillop Does Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review J. Clin. Oncol., February 1, 2003; 21(3): 555 - 563. [Abstract] [Full Text] [PDF]

				G. R. Simon and H. Wagner Small Cell Lung Cancer Chest, January 1, 2003; 123(1_suppl): 259S - 271S. [Abstract] [Full Text] [PDF]

				S. G. Spiro and J. C. Porter Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1166 - 1196. [Abstract] [Full Text] [PDF]

				M. Machtay The Early Rad Catches the Tumor? J. Clin. Oncol., July 15, 2002; 20(14): 3045 - 3047. [Full Text] [PDF]

				M. Takada, M. Fukuoka, M. Kawahara, T. Sugiura, A. Yokoyama, S. Yokota, Y. Nishiwaki, K. Watanabe, K. Noda, T. Tamura, et al. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Cisplatin and Etoposide for Limited-Stage Small-Cell Lung Cancer: Results of the Japan Clinical Oncology Group Study 9104 J. Clin. Oncol., July 15, 2002; 20(14): 3054 - 3060. [Abstract] [Full Text] [PDF]

				K. Osterlind Chemotherapy in small cell lung cancer Eur. Respir. J., December 1, 2001; 18(6): 1026 - 1043. [Abstract] [Full Text] [PDF]

				I. S. Woo, Y. S. Park, S. H. Kwon, Y. I. Park, J. A. Lee, M. J. Park, I. G. Hyun, K. S. Jung, H. S. Bae, D. H. Oh, et al. A Phase II Study of VP-16-Ifosfamide-Cisplatin Combination Chemotherapy Plus Early Concurrent Thoracic Irradiation for Previously Untreated Limited Small Cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2000; 30(12): 542 - 546. [Abstract] [Full Text] [PDF]

				A. Hugli, D. Moro, B. Mermillod, M. Bolla, P. Alberto, H. Bonnefoi, and R. Miralbell Phase II Trial of Up-Front Accelerated Thoracic Radiotherapy Combined With Chemotherapy and Optional Up-Front Prophylactic Cranial Irradiation in Limited Small-Cell Lung Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1662 - 1667. [Abstract] [Full Text] [PDF]

				D. H. Johnson Management of Small Cell Lung Cancer* : Current State of the Art Chest, December 1, 1999; 116(suppl_3): 525S - 530S. [Abstract] [Full Text] [PDF]